Literature DB >> 27602131

p21 participates in the regulation of anaplastic thyroid cancer cell proliferation by miR-146b.

Shiyang Wang1, Yangjing Chen1, Yanxia Bai1.   

Abstract

Anaplastic thyroid carcinoma (ATC) originates from completely undifferentiated cells, and is the most lethal type of thyroid-derived tumor. Numerous microRNAs have significant roles in tumorigenesis by targeting relevant genes. The role of microRNA 146b (miR-146b) in ATC remains to be elucidated. In order to characterize the role of miR-146b in ATC, overexpression or interference of miR-146b was induced in ATC cell lines, and cell proliferation and migration were evaluated. The potential targets of miR-146b were searched in the Gene Expression Omnibus database for ATC and matched non-tumor control samples. The expression level of potential targets was detected following overexpression or interference of miR-146b in ATC cell lines. In the present study, cell proliferation was promoted when overexpression of miR-146b was induced in ATC, and inhibited when interference of miR-146b was induced, which indicated that miR-146b affects the proliferation of ATC cells in vitro. In addition, cell migration of ATC was also affected by miR-146b. During the search for potential targets of miR-146b in ATC, p21 (also known as p21Waf1/Cip1 or CDKN1A) was noted for its role in cell cycle progression and tumor pathogenesis. The expression level of p21 was influenced by the level of miR-146b, and the results of the present study demonstrated that the level of p21 was increased when FRO cells were transformed with miR-146b mimic, and p21 was downregulated when FRO cells transformed with anti-miR-146b. In conclusion, p21 may participate in the regulation of ATC cell proliferation by miR-146b.

Entities:  

Keywords:  anaplastic thyroid carcinoma; cell proliferation; microRNA-146b; oncogenesis; p21

Year:  2016        PMID: 27602131      PMCID: PMC4998571          DOI: 10.3892/ol.2016.4874

Source DB:  PubMed          Journal:  Oncol Lett        ISSN: 1792-1074            Impact factor:   2.967


  30 in total

1.  Analysis of relative gene expression data using real-time quantitative PCR and the 2(-Delta Delta C(T)) Method.

Authors:  K J Livak; T D Schmittgen
Journal:  Methods       Date:  2001-12       Impact factor: 3.608

2.  A novel human p53 isoform is an essential element of the ATR-intra-S phase checkpoint.

Authors:  Gabor Rohaly; Jan Chemnitz; Silke Dehde; Alejandro Mena Nunez; Jochen Heukeshoven; Wolfgang Deppert; Irena Dornreiter
Journal:  Cell       Date:  2005-07-15       Impact factor: 41.582

Review 3.  Ras, PI(3)K and mTOR signalling controls tumour cell growth.

Authors:  Reuben J Shaw; Lewis C Cantley
Journal:  Nature       Date:  2006-05-25       Impact factor: 49.962

4.  MiR-663, a microRNA targeting p21(WAF1/CIP1), promotes the proliferation and tumorigenesis of nasopharyngeal carcinoma.

Authors:  C Yi; Q Wang; L Wang; Y Huang; L Li; L Liu; X Zhou; G Xie; T Kang; H Wang; M Zeng; J Ma; Y Zeng; J-P Yun
Journal:  Oncogene       Date:  2012-01-16       Impact factor: 9.867

Review 5.  Anaplastic thyroid carcinoma: pathogenesis and emerging therapies.

Authors:  R C Smallridge; J A Copland
Journal:  Clin Oncol (R Coll Radiol)       Date:  2010-04-24       Impact factor: 4.126

6.  p21/CDKN1A mediates negative regulation of transcription by p53.

Authors:  Kristina Löhr; Constanze Möritz; Ana Contente; Matthias Dobbelstein
Journal:  J Biol Chem       Date:  2003-05-13       Impact factor: 5.157

7.  Specific microRNAs are downregulated in human thyroid anaplastic carcinomas.

Authors:  R Visone; P Pallante; A Vecchione; R Cirombella; M Ferracin; A Ferraro; S Volinia; S Coluzzi; V Leone; E Borbone; C-G Liu; F Petrocca; G Troncone; G A Calin; A Scarpa; C Colato; G Tallini; M Santoro; C M Croce; A Fusco
Journal:  Oncogene       Date:  2007-06-11       Impact factor: 9.867

8.  Deoxyribonucleic acid profiling analysis of 40 human thyroid cancer cell lines reveals cross-contamination resulting in cell line redundancy and misidentification.

Authors:  Rebecca E Schweppe; Joshua P Klopper; Christopher Korch; Umarani Pugazhenthi; Miriam Benezra; Jeffrey A Knauf; James A Fagin; Laura A Marlow; John A Copland; Robert C Smallridge; Bryan R Haugen
Journal:  J Clin Endocrinol Metab       Date:  2008-08-19       Impact factor: 5.958

Review 9.  Improving the adoption of thyroid cancer clinical practice guidelines.

Authors:  Ilya Likhterov; R Michael Tuttle; Grace C Haser; Henry K Su; Donald Bergman; Eran E Alon; Victor Bernet; Elise Brett; Rhoda Cobin; Eliza H Dewey; Gerard Doherty; Laura L Dos Reis; Joshua Klopper; Stephanie L Lee; Mark A Lupo; Josef Machac; Jeffrey I Mechanick; Mira Milas; Lisa Orloff; Gregory Randolph; Douglas S Ross; Meghan E Rowe; Robert Smallridge; David Terris; Ralph P Tufano; Mark L Urken
Journal:  Laryngoscope       Date:  2016-04-14       Impact factor: 3.325

10.  Multiple microRNAs rescue from Ras-induced senescence by inhibiting p21(Waf1/Cip1).

Authors:  V Borgdorff; M E Lleonart; C L Bishop; D Fessart; A H Bergin; M G Overhoff; D H Beach
Journal:  Oncogene       Date:  2010-01-25       Impact factor: 9.867

View more
  3 in total

Review 1.  MicroRNA-146b: A Novel Biomarker and Therapeutic Target for Human Papillary Thyroid Cancer.

Authors:  Chen-Kai Chou; Rue-Tusan Liu; Hong-Yo Kang
Journal:  Int J Mol Sci       Date:  2017-03-15       Impact factor: 5.923

2.  Study on the value of serum miR-106b for the early diagnosis of hepatocellular carcinoma.

Authors:  Bao-Min Shi; Wen Lu; Kun Ji; Yu-Feng Wang; Shuai Xiao; Xiu-Yan Wang
Journal:  World J Gastroenterol       Date:  2017-05-28       Impact factor: 5.742

3.  C5aR deficiency attenuates the breast cancer development via the p38/p21 axis.

Authors:  Jian Chen; Zi-Han Sun; Li-Ying Chen; Feng Xu; Yun-Pei Zhao; Gui-Qing Li; Ming Tang; You Li; Quan-You Zheng; Shu-Feng Wang; Xin-Hua Yang; Yu-Zhang Wu; Gui-Lian Xu
Journal:  Aging (Albany NY)       Date:  2020-07-15       Impact factor: 5.682

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.